免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (8): 1210-1215.

免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展

张若曦, 韩冰^*

中国医学科学院北京协和医学院北京协和医院血液科,北京 100730

收稿日期:2020-05-21 修回日期:2020-10-10 出版日期:2021-08-05 发布日期:2021-07-21
通讯作者: *hanbing_li@sina.com.cn
基金资助:
北京自然科学基金(7192168);中国医学科学院医学创新基金(2016-I2M-3-004);中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2020)

Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome

ZHANG Ruo-xi, HAN Bing^*

Department of Hematology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2020-05-21 Revised:2020-10-10 Online:2021-08-05 Published:2021-07-21
Contact: *hanbing_li@sina.com.cn

摘要/Abstract

摘要： 免疫检查点抑制剂(ICI)通过抑制肿瘤细胞逃逸、增强免疫应答而作为MDS潜在的治疗方式,本文回顾性分析了针对PD-1/PD-L1和CTLA-4的ICI治疗MDS的临床试验,分析了ICI治疗的疗效和不良反应。ICI单药或与去甲基化药物(HMA)合用是可耐受的。尽管目前单药ICI治疗的疗效有限,但和HMA可能具有协同作用,且对于HMA无效患者可作为一种潜在的选择。尽管存在免疫相关不良反应(irAEs),但多数可通过类固醇逆转。

关键词: 免疫检查点抑制剂, 骨髓异常增生综合征, 疗效, 安全性

Abstract: Immune checkpoint inhibitor(ICI) is a potential treatment for MDS by inhibiting the escape of tumor cells and enhancing immune responses. This article reviewed the efficacy and adverse events of clinical trials focusing on PD-1/PD-L1 and CTLA-4 inhibitors on MDS patients. Although the efficacy of single-agent ICI therapy was limited, it may have a synergistic effect with hypomethylation agent (HMA), which could be a choice for patients who fail to respond to HMA treatment. Immune-related adverse events(irAE) were observed, but most can be reversed by steroids.

Key words: immune checkpoint inhibitor, myelodysplastic syndrome, efficacy, safety

中图分类号:

R551

张若曦, 韩冰. 免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展[J]. 基础医学与临床, 2021, 41(8): 1210-1215.

ZHANG Ruo-xi, HAN Bing. Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome[J]. Basic & Clinical Medicine, 2021, 41(8): 1210-1215.

参考文献

[1]Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381:1535-1546.
[2]Morita R, Okishio K, Shimizu J, et al. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: a multicenter retrospective observational study in Japan[J]. Lung Cancer, 2020, 140:8-18.
[3]Yang H, Bueso-Ramos C, DiNardo C, et al.Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J]. Leukemia, 2014, 28:1280-1288.
[4]Yang H, Fang Z, Clise-Dwyer K, et al. Induced PD-1 expression on bone marrow CD34⁺ Cells from MDS patients treated with 5-Azacitadine in combination with Nivolumab and/or Ipilimumab[J]. Blood, 2018, 132 (Supplement 1): 1807.doi:10.1182/blood-2018-99-119278.
[5]Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses[J]. Cell, 2017, 169:361.doi:10.1016/j.cell.2015.07.11.
[6]Syn NL, Teng MWL, Mok TSK, et al. De-novo and acquired resistance to immune checkpoint targeting[J]. Lancet Oncology, 2017, 18:e731-e741.
[7]Garcia-Manero G, Tallman MS, Martinelli G, et al. Pembrolizumab, a PD-1 inhibitor, in patients with melodysplastic syndrome (MDS) after failure of hypomethylating agent treatment[J]. Blood, 2016, 128: 345.doi:10.1182/blood-2019-129598.
[8]Chien KS, Borthakur GM, Naqvi K, et al. Updated preliminary results from a phase Ⅱ study combining Azacitidine and Pembrolizumab in patients with higher-risk myelodysplastic syndrome[J]. Blood, 2019, 134(Supplement 1): 4240.doi:10.1182/blood-2019-129598.
[9]Zeidan AM, Cavenagh J, Voso MT, et al. Efficacy and safety of Azacitidine (AZA) in combination with the anti-PD-L1 Durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and pts with higher-risk myelodysplastic syndromes (HR-MDS): results from a large, international, randomized phase 2 Study[J]. Blood, 2019, 134 (Supplement 1): 829.doi:10.1182/blood-2019-122896.
[10]O'Cennell CL, Kropf PL, Punwani N, et al. Phase I results of a multicenter clinical trial combining Guadecitabine, a DNA methyltransferase inhibitor, with Atezolizumab, an immune checkpoint inhibitor, in patients with relapsed or refractory myelodysplastic syndrome or chronic myelomonocytic leukemia[J]. Blood, 2018, 132(supplement 1): 1811.doi:10.1182/blood-2018-99-117658.
[11]Zeidan AM, Knaus HA, Robinson TM, et al. A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure[J]. Clin Cancer Res, 2018, 24:3519-3527.
[12]Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation[J]. N Engl J Med, 2016, 375:143-153.
[13]Robinson TM, Knaus H, Smith D, et al. Immunological correlates of treatment with the CTLA-4 inhibitor Ipilimumab in patients with refractory myelodysplastic syndromes (MDS)[J]. Blood, 2017,130(supplement 1): 1699.doi:10.1182/blood.V30.Suppl-1.1699.1699.
[14]Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. A phase Ⅱ study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)[J]. Blood, 2018, 132(supplement 1): 465.doi:10.1182/blood-2018-99-119424.
[15]Daver N, Boddu P, Garcia-Manero G, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes[J]. Leukemia, 2018, 32: 1094-1105.
[16]Garcia-Manero G, Montalban-Bravo G, Sasaki K, et al. Double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome[J]. Blood, 2018, 132(supplement 1): 1831.doi:10.1182/blood-2018-99-118948.
[17]Rausch CR, Paul S, Montalban-Bravo G, et al.Pattern of immune-mediated toxicities in patients with myelodys-plastic syndrome (MDS) treated with Nivolumab and Ipilimumab[J]. Blood, 2018, 132(supplement 1): 4367.doi:10.1182/blood-2018-99-116714.
[18]Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition[J]. N Engl J Med, 2017, 377:2500-2501.